Pentixapharm Holding AG (ETR:PTP)

PRESS RELEASE

published on 10/01/2024 at 18:48, 1 year 5 months ago

EQS-Adhoc: Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed
Pentixapharm Holding AG sets IPO placement price at EUR 5.10 per share, placing all 3.9 million offer shares. Gross proceeds reach EUR 19.9 million. Post-money market capitalization at EUR 126.5 million

IPO Market Capitalization Pentixapharm Holding AG Placement Price Offer Shares
PRESS RELEASE

published on 09/24/2024 at 11:51, 1 year 6 months ago

Original-Research: Pentixapharm Holding AG (von BankM AG): n.a.
Pentixapharm Holding AG von BankM AG eingestuft. Präziser Theranostic-Ansatz mit validiertem Target. Potenzial in Präzisionsonkologie. Risikoadjustierte Bewertung des Eigenkapitals. Vollständige Analyse unter: http://www.more-ir.de/d/30855.pdf

BankM AG Pentixapharm Holding AG Theranostic-Ansatz Präzisionsonkologie Bewertung Eigenkapital
BRIEF

published on 09/23/2024 at 12:20, 1 year 6 months ago

Pentixapharm Holding AG fixe la fourchette de prix de son introduction en bourse

Bourse De Francfort Essais Cliniques Introduction En Bourse Produits Radiopharmaceutiques Pentixapharm
BRIEF

published on 09/23/2024 at 12:20, 1 year 6 months ago

Pentixapharm Holding AG Sets Price Range for Planned IPO

Frankfurt Stock Exchange Clinical Trials IPO Radiopharmaceuticals Pentixapharm
PRESS RELEASE

published on 09/23/2024 at 12:15, 1 year 6 months ago

Pentixapharm Holding AG Sets Price Range for Planned IPO
Pentixapharm Holding AG sets price range of EUR 4.70 to EUR 6.00 per share for planned IPO to fund product pipeline development in radioligand therapies

IPO Financial Resources Price Range Pentixapharm Holding AG Radioligand Therapies
BRIEF

published on 09/12/2024 at 15:05, 1 year 6 months ago

Pentixapharm Holding AG Plans IPO on Frankfurt Stock Exchange

Frankfurt Stock Exchange Cancer Treatment IPO Radiopharmaceuticals Phase III Trials
BRIEF

published on 09/12/2024 at 15:05, 1 year 6 months ago

Pentixapharm Holding AG envisage une introduction en bourse à Francfort

Bourse De Francfort Introduction En Bourse Traitement Du Cancer Produits Radiopharmaceutiques Essais De Phase III
PRESS RELEASE

published on 09/12/2024 at 15:00, 1 year 6 months ago

Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
Pentixapharm Holding AG, a subsidiary of Eckert & Ziegler SE, plans IPO on the Prime Standard of the Frankfurt Stock Exchange, focusing on innovative radiopharmaceuticals for theranostics of various indications

Frankfurt Stock Exchange IPO Radiopharmaceuticals Pentixapharm Holding AG Theranostics

Published on 03/26/2026 at 14:05, 1 hour 45 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 2 hours 50 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 2 hours 50 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 2 hours 51 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 3 hours 5 minutes ago

Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia

View all ACCESSWIRE

Published on 03/26/2026 at 15:25, 25 minutes ago

Duck Creek Loss Control Named 2026 Insurance Luminary Finalist by PropertyCasualty360
Published on 03/26/2026 at 15:23, 26 minutes ago

Sartorius AG - Resolutions of the Annual General Meeting
Published on 03/26/2026 at 15:05, 45 minutes ago

JOY GROUP Announces 2025 Financial Results, Revenue Surpasses US$620M
Published on 03/26/2026 at 15:01, 48 minutes ago

EQS-Adhoc: CENIT AG decides to switch from the Regulated Market (Prime Standard) to the Scale Segment of the Frankfurt Stock Exchange
Published on 03/26/2026 at 15:00, 50 minutes ago

OLB’s financial performance remains at a consistently high level

View all EQS

Published on 03/26/2026 at 08:57, 6 hours 52 minutes ago

Communiqué Edenred
Published on 03/26/2026 at 08:57, 6 hours 52 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 8 hours 20 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/26/2026 at 07:30, 8 hours 20 minutes ago

BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ
Published on 03/25/2026 at 18:53, 20 hours 56 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026

View all LES ECHOS COMFI WIRE

News